JC06 Rec'd PCT/PTO 09 SEP 2005 PC

State: September 8, 2005 I hereby by that, on the date-indicated above, I deposite by paper with identified attachments and/or fee with the U.S. Postal Service and that it was addressed for delivery to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 by "First Class Mail" service.

Kim Blum
Name (Print)

Signatura

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: ENDO et al.

Application No.: 10/522,000

Filed: January 18, 2005

Docket No.: 3190-071

Examiner: Unassigned

Confirmation No.: 6735

Customer No.: 33432

For: SINGLE CHAIN ANTIBODY AND USE THEREOF

RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

September 8, 2005

Sir:

In response to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures dated August 9, 2005, the applicants respond as follows.

In the Notification, it was asserted that an additional claim fee of \$50.00 is due. Applicants respectfully disagree. In applicant's preliminary amendment dated January 18, 2005, applicants canceled claims 10, 11, and 17 reducing the number of claims filed from 28 to 25. Applicants did, however, pay for the 5 additional extra dependent claims at the time of filing of the above-identified application.

Also in the Notification, it was asserted that the content of the computer readable form does not comply with the requirements of 37 C.F.R. §1.822 and/or § 1.823.

To fully respond to this Notification, the paper copy of the Sequence Listing is amended by the submission of substitute sheets, attached hereto. The amendment to the Sequence Listing Response to Notification to Comply With Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures U.S. Patent Application No. 10/522,000

is limited to formal matters, specifically, a correction to item <211> for SEQ ID NO:1 to correctly indicate that the number of nucleotide bases in the sequence is 45 and an amendment to item <140> to reflect the current assigned U.S. patent application number for the present application. No new matter is added to the Sequence Listing. Also enclosed is a substitute diskette containing a computer readable form of the amended "Sequence Listing." Also enclosed is a Statement under 37 C.F.R. § 1.821. Accordingly, the applicants have fully responded to the notification.

CONCLUSION

In view of the foregoing remarks, the applicant respectfully requests the reconsideration of this application and the timely allowance of the pending claims.

If there are any fees due in connection with the filing of this response, please charge the fees to Deposit Account No. 50-0925. If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such extension is requested and should also be charged to said Deposit Account.

Respectfully submitted,

Luke A. Kilyk

Reg. No. 33,251

Atty. Docket No. 3190-071

KILYK & BOWERSOX, P.L.L.C.

53 A East Lee Street

Warrenton, VA 20186

Tel.: (540) 428-1701 Fax: (540) 428-1720

Enclosures: Statement Under 37 C.F.R. § 1.821

Printed version of the "Sequence Listing"

Diskette containing a computer readable form of the "Sequence Listing."

Copy of Notice to Comply with Requirements